|
FDA approves ticagrelor (Brilinta) to treat acute coronary syndrome. |
 |
 |
|
FDA: The U.S. Food and Drug Administration today approved the blood-thinning drug Brilinta (ticagrelor) to reduce cardiovascular death and heart attack in patients with acute coronary syndromes (ACS). ACS includes a group of symptoms for any condition, such as unstable angina or heart attack, that could result from reduced blood flow to the heart. Brilinta works by preventing the formation of new blood clots, thus maintaining blood flow in the body to help reduce the risk of another cardiovascular event.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
